Tempus AI, Inc.

Tempus AI reports two revenue lines: Genomics (lab testing/sequencing) and Data & Services (data licensing, analytics, clinical trial matching). Genomics revenue of $82.1M is primarily a biochemistry/lab service business — revenue is recognized upon delivery of test results and priced at standard clinical reimbursement rates (Medicare CPT codes). AI adds interpretive value (~10% attribution) through algorithmic therapy matching and Intelligent Diagnostics contextualization, but the core service is laboratory sequencing. Data & Services revenue of $33.6M includes Insights (de-identified data licensing, analytical services, Lens AI platform access) and Trials (algorithmic patient-trial matching). ~60% attributed to AI given mix of raw data licensing (less AI) and AI-powered analytics/matching. AI revenue estimate: ($82.1M x 10%) + ($33.6M x 60%) = $8.2M + $20.2M = $28.4M of $115.6M total = 24.5%. Derived from H1 FY2023 figures minus Q2 FY2023.